I-MODInfinity Modulator (Star Trek)
References in periodicals archive ?
Reeves quoted Immune Technologies as reporting, in their clinical trials, I-MOD ER(TM) had a cure rate of 79% in the first phase and 100% in the second phase, with no adverse reactions.
OTCBB:BNTK) President Alan Schafler and Lea Dowd, CEO for Immune Technologies, are pleased to announce that I-MOD ER(TM), Immune Technologies' immunomodulator for equine respiratory diseases, continues to move forward in pre-licensing.
Her extensive experience and research and development work has led to the development of the Dowd technology and the company's I-MOD product line.